简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:BENGALURU, June 5 (Reuters) - Indian shares settled higher on Monday, propped by sustained gains in
BENGALURU, June 5 (Reuters) - Indian shares settled higher on Monday, propped by sustained gains in auto stocks and on stronger bets that the Federal Reserve may skip an interest rate hike later this month.
The blue-chip Nifty 50 (.NSEI) index closed 0.32% higher at 18,593.85, while the benchmark S&P BSE Sensex (.BSESN) finished 0.38% up to 62,787.47.
Both the indexes registered their second-straight weekly gain on Friday, lifted by stronger-than-expected economic growth data and fast-paced expansion of the countrys factory output.
\“The Nifty has a strong support around 18,200 level, while an immediate resistance is at around 18,700 we expect some consolidation at those higher levels in the next few weeks with the index possibly testing all-time high levels,\” said Neeraj Dewan, an independent market analyst. The index has scaled 9.7% from March lows.
The focus is on the monetary policy meetings in the U.S. and India and the progress of monsoons as the countrys economy depends on agriculture to a large extent, Dewan added.
Global shares rose on Monday on optimism the Fed would pause rate hikes this month after data showed that while the U.S. economy added 339,000 jobs last month, wage growth moderated and the unemployment rate rose.
This week, investors will closely watch the Reserve Bank of Indias monetary policy decision. The central bank is expected to leave its key interest rate unchanged on June 8 and for the rest of 2023, a Reuters poll of economists showed.
Among the 13 major Nifty indexes, autos (.NIFTYAUTO) added over 1% to hit a record high for a second straight session after the May data for top automakers showed robust sales.
Mankind Pharma Ltd (MNKI.NS) closed 2.9% lower after the companys cough syrups such as Codistar and Tedykoff were pulled off the shelves following a ban of 14 fixed dose drug combinations over the weekend by the government, according to local media.
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.